メニュー
Recommends against routine 25(OH)D testing during pregnancy. Triggers include: "Should I order a vitamin D level for this pregnant patient?" and "Is vitamin D testing indicated for asymptomatic pregnant patients?"
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-vitd-no-testing-pregnancyコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
SOC 職業分類に基づく
SKILL.md を表示中
| name | endo-vitd-no-testing-pregnancy |
| description | Recommends against routine 25(OH)D testing during pregnancy. Triggers include: "Should I order a vitamin D level for this pregnant patient?" and "Is vitamin D testing indicated for asymptomatic pregnant patients?" |
Confirm pregnancy status and assess for symptoms or conditions indicating vitamin D deficiency (e.g., hypocalcemia, seizures, cardiomyopathy, malabsorption, renal/hepatic disease, medications affecting vitamin D). Collect gestational age, dietary/supplement intake, and risk factors; if asymptomatic and no established indications, proceed to next step.
Rule out established indications for 25(OH)D testing: presence of hypocalcemia, symptomatic vitamin D deficiency, malabsorption syndromes, chronic kidney/liver disease, or use of anticonvulsants/glucocorticoids. If any indication is present, testing may be warranted; otherwise, rule out need for routine testing.
Classify the patient as pregnant without established indications for vitamin D testing (i.e., asymptomatic for deficiency and no comorbid conditions that alter vitamin D physiology).
Do not order routine 25(OH)D testing; consider empiric vitamin D supplementation via prenatal vitamin or fortified foods as per guideline Recommendation 8, and reassure the patient that testing is unnecessary in this context.
Do not test solely for screening in asymptomatic pregnant patients; do not delay supplementation awaiting test results; avoid using testing to guide vitamin D dosing in pregnancy without symptoms; recognize that testing may be appropriate if symptoms of deficiency (e.g., hypocalcemic seizures, cardiomyopathy) arise; note that dark complexion or obesity alone do not indicate testing without clinical signs.
A 28‑year‑old woman at 16 weeks gestation presents for routine prenatal care, reports no bone pain, muscle weakness, or seizures, and takes a prenatal vitamin containing 400 IU vitamin D daily. She asks whether she should have her vitamin D level checked. According to the guideline, routine testing is not indicated; she is reassured that empiric supplementation via her prenatal vitamin is appropriate and testing is unnecessary unless symptoms develop.
Source: Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2024, https://doi.org/10.1210/clinem/dgae290